<International Circulation>：The International Stroke Conference (ISC) is the world’s largest meeting dedicated to the science and treatment of cerebrovascular disease. As chair of ISC 2013， could please comment on what your hopes are for this year’s meeting? What do you think are the hot topics this year?

　　《国际循环网》：国际卒中大会（ISC）是世界上最大的致力于脑血管疾病研究和治疗的盛会。作为2013 ISC主席，请您谈谈对今年会议有哪些期望？热点问题有哪些？

　Prof.Greenberg: This year’s ISC， like every year’s conference will really be driven by the scientific sessions presented. The scientific sessions will be presented in multiple forms such as posters， oral abstracts and invited sessions such as pre-conference symposiums covering particularly active or novel areas related to stroke. There will also be presentations on late-breaking usually clinical trials related to stroke. These trials are often the feature of the meeting and get the most publicity. There is a wide range of types of scientific abstracts that will be presented but just to highlight a few there will be the usual group of recently breaking clinical trials. Notable among those will be two major trials of intra-arterial endovascular therapy for acute stroke. There will be the MR RESCUE (The Mechanical Retrieval and REcanalization of Stroke Clots Using Embolectomy) study and the IMS Ⅲ (Interventional Management of Stroke III Trial) study both of which will be presented for the first time publically at ISC. In this really active and quickly changing field and there is the question of when to choose intra-arterial and endovascular therapy for acute stroke as opposed to already established therapies， like intra-venous tissue plasminogen activator (tPA) for acute stroke. The conference will also include another much-awaited trial not in acute stroke therapy but in prevention is the SPS3 (Secondary Prevention of Small Subcortical Strokes Trial) study which is the trial on the prevention of recurrence small strokes which we know are important contributor to long-term disability and vascular cognitive impairment. This study has been done in two arms. One of the arms has already been reported as not being effective which was the addition of a second antiplatelet treatment， clopidogrel on top of aspirin. The result presented at this meeting will address the other arm which involves a very tight blood pressure control as opposed to more lose， conventional blood pressure control and the other trial presented as well.

　　Greenberg 教授: 和往年一样，今年会议的热点也将会是科学会议的展示。展示方式多样，例如，海报、口头演讲以及邀请会话，如涵盖卒中相关领域的热点问题及最新进展的会前讨论会。也有卒中最新临床研究的展示。这些临床研究常为会议特色并得到最广泛关注。ISC会议也将展出涉及各方面各种形式的研究摘要，其中临床试验最新研究突破最为突出，最值得一提的是两个关于急性卒中的动脉内血管治疗的大型临床试验。MR RESCUE（The Mechanical Retrieval and REcanalization of Stroke Clots Using Embolectomy）研究和IMS Ⅲ（Interventional Management of Stroke III Trial）研究将首次在ISC会议上公布。与已建立的治疗方法如静脉内注射组织纤溶酶原激活物（t-PA）治疗急性卒中相比，何时选择动脉内血管治疗急性卒中值得商榷。还有一个备受关注的关于反复发作性小卒中预防的临床试验——SPS3（Secondary Prevention of Small Subcortical Strokes Trial)）研究，我们知道反复发作性小卒中会导致长期躯体功能障碍及血管性认知功能损害。研究者从两方面进行研究，一个方面是已经报道的关于抗血小板治疗的附加用药，即阿司匹林联合氯吡格雷，此试验结果证实无效。今年ISC，研究者将展示此试验的另一方面研究结果，即对反复小卒中发作的患者进行严格的血压控制，与传统较松散的血压控制及其他研究结果对比。
Also， for the first time， this year we will have a rapid-fire of shot presentations related to possible future stroke developments: “the next best thing in stroke at lightning speed.” We have asked eleven experts asked to give five minute speeches rather than our usually talk being driven primarily data and very careful descriptions of what has been done. Instead we will turn， not to science fiction， but to realistic views of what the future might hold. We are using the rapid-fire format to have a little fun but also to stimulate people to think in a forward-looking way and to stimulate discussion among the audience. So， this will be the first time we have used this format at the International Stroke Conference and we are looking forward to seeing how it does with engaging the audience.

　　今年ISC新增的环节是速射展示卒中研究领域未来可能发展前景：“在最短的时间内报告卒中研究将会有的突破”。我们已邀请11位专家做5分钟演讲，摒弃传统的数据罗列和审慎描述已完成工作的模式。我们将转而关注未来发展的切实可行的观点，而不是不切实际的幻想。我们利用速射方式目的是使现场气氛更加活跃，引导观众参与讨论，并以展望的方式思考。因此，这将是我们首次在ISC会议中展开这种模式的讨论，我们期待知道对观众是否有吸引力。

One other unique feature of this year’s meeting will be a special contribution to C. Miller Fisher. Dr. Fisher would have turned 100 in 2013 but passed away in April of 2012 and there will be several tributes to Dr. Fisher. Although there have been many great contributors to the stroke field， Dr. C. Miller Fisher was a once in a generation giant as he has made an enormous contribution to our modern understanding of stroke. One of the symposiums will highlight the way Dr. Miller Fisher’s contribution continues to influence the direction of stroke research in multiple areas.

　　今年ISC另一亮点是C. Miller Fisher的特殊贡献。2013年Fisher博士本应100岁，但不幸的是，他在2012年4月永远离开了我们，因此，会上将会有对Dr. Fisher的颂词。尽管在卒中研究领域有很多优秀贡献者，C. Miller Fisher博士无疑是这个时代的巨人，他对近代卒中发展做出巨大贡献。其中一个专题，将强调Miller Fisher博士如何在多个领域持续影响卒中研究方向。